If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksChemring Regulatory News (CHG)

Share Price Information for Chemring (CHG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 385.50
Bid: 384.50
Ask: 385.50
Change: -1.00 (-0.26%)
Spread: 1.00 (0.26%)
Open: 389.00
High: 389.00
Low: 383.50
Prev. Close: 386.50
CHG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Funding Awards

18 Mar 2024 07:00

RNS Number : 1412H
Chemring Group PLC
18 March 2024
 

FOR IMMEDIATE RELEASE 18 MARCH 2024

 

CHEMRING GROUP PLC ("Chemring", the "Group" or the "Company")

 

c.£90m FUNDING AWARDS

 

Chemring notes the announcement made by the European Commission regarding its allocation of funding in support of boosting defence production within Europe, and we welcome its public announcement of awards totaling ?66.7m (£57m) made to our Norwegian subsidiary, Chemring Nobel.

 

These awards, which are part of the Act in Support of Ammunition Production ("ASAP") programme, are a direct response to the European Council's call in March 2023 to urgently deliver ammunition, and missiles if requested, to Ukraine and to help Member States refill their stocks by introducing targeted measures. This Regulation aims to strengthen the responsiveness and ability of the European Union's defence industry to ensure the timely supply of ammunition and missiles in Europe, and includes measures to support production capacities and tackle identified bottlenecks throughout the industrial supply chain.

 

Further information can be found on the European Commission website: https://defence-industry-space.ec.europa.eu/eu-defence-industry/asap-boosting-defence-production_en

 

Chemring is also pleased to report that it has received further grant funding of 428 million NOK (£32m) from the Government of Norway. This co-financing will boost capacity and production at Chemring Nobel and will significantly strengthen Norwegian production capacity for critical defense products.

 

Further information can be found on the Norwegian government website: https://www.regjeringen.no/no/aktuelt/milliardstotte-til-norsk-forsvarsindustri/id3029866/.

 

Grant agreements are expected to be signed over the coming months.

 

Both grants support Chemring's decision to invest in doubling the capacity of this facility over the medium-term, and reinforces Chemring Nobel's position as a key strategic supplier to NATO.

 

 

For further information:

Rupert Pittman Group Director of Corporate Affairs, 01794 463401

Chemring Group PLC

 

James McFarlane MHP Communications 020 3128 8100

Ollie Hoare

Cautionary statement

 

This announcement contains forward-looking statements that are based on current expectations or beliefs, as well as assumptions about future events. These forward-looking statements can be identified by the fact that they do not relate only to historical or current facts. Forward-looking statements often use words such as anticipate, target, expect, estimate, intend, plan, goal, believe, will, may, should, would, could, is confident, or other words of similar meaning. Undue reliance should not be placed on any such statements because they speak only as at the date of this document and, by their very nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results, and Chemring's plans and objectives, to differ materially from those expressed or implied in the forward-looking statements. There are a number of factors which could cause actual results to differ materially from those expressed or implied in forward-looking statements. Among the factors that could cause actual results to differ materially from those described in the forward-looking statements are: increased competition, the loss of or damage to one or more key customer relationships, changes to customer ordering patterns, delays in obtaining customer approvals for engineering or price level changes, the failure of one or more key suppliers, the outcome of business or industry restructuring, the outcome of any litigation, changes in economic conditions, currency fluctuations, changes in interest and tax rates, changes in raw material or energy market prices, changes in laws, regulations or regulatory policies, developments in legal or public policy doctrines, technological developments, the failure to retain key management, or the key timing and success of future acquisition opportunities or major investment projects. Chemring undertakes no obligation to revise or update any forward-looking statement contained within this announcement, regardless of whether those statements are affected as a result of new information, future events or otherwise, save as required by law and regulations.

 

Notes to editors

 

· Chemring is a FTSE250 global business that specialises in the manufacture of high technology products and the provision of services to the aerospace, defence and security markets

· Employing approximately 2,600 people worldwide, and with production facilities in four countries, Chemring meets the needs of customers in more than fifty countries

· Chemring is organised under two strategic product segments: Sensors & Information and Countermeasures & Energetics

· Chemring has a diverse portfolio of products that deliver high reliability solutions to protect people, platforms, missions and information against constantly changing threats

· Operating in niche markets and with strong investment in research and development ("R&D"), Chemring has the agility to rapidly react to urgent customer needs

 

www.chemring.com.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
STRQKOBPPBKDPND
Date   Source Headline
14th Jul 202012:07 pmRNSSecond Price Monitoring Extn
14th Jul 202012:02 pmRNSPrice Monitoring Extension
10th Jul 202012:07 pmRNSSecond Price Monitoring Extn
10th Jul 202012:02 pmRNSPrice Monitoring Extension
8th Jul 202012:07 pmRNSSecond Price Monitoring Extn
8th Jul 202012:02 pmRNSPrice Monitoring Extension
7th Jul 20204:02 pmRNSHolding(s) in Company
6th Jul 20202:03 pmRNSHolding(s) in Company
6th Jul 20201:58 pmRNSHolding(s) in Company
2nd Jul 202012:02 pmRNSPrice Monitoring Extension
1st Jul 202011:36 amRNSTotal Voting Rights
22nd Jun 20204:26 pmRNSDirector/PDMR Shareholding
19th Jun 20209:34 amRNSBlock listing update
19th Jun 20209:28 amRNSBlock listing Interim Review
3rd Jun 20207:00 amRNSDirectorate Change
3rd Jun 20207:00 amRNSInterim Results
1st Jun 20209:20 amRNSTotal Voting Rights
27th May 202011:16 amRNSHolding(s) in Company
7th May 20207:00 amRNSCompletion of disposal
1st May 202011:39 amRNSTotal Voting Rights
29th Apr 202010:31 amRNSDisclosure of Rights Attached to Equity Shares
20th Apr 20207:05 amRNSDirector Declaration
14th Apr 20207:00 amRNSCovid-19 Update
7th Apr 202012:07 pmRNSSecond Price Monitoring Extn
7th Apr 202012:02 pmRNSPrice Monitoring Extension
3rd Apr 202012:34 pmRNSTotal Voting Rights
1st Apr 20201:36 pmRNSTotal Voting Rights
30th Mar 20204:09 pmRNSHolding(s) in Company
25th Mar 202012:57 pmRNSDirector/PDMR Shareholding
24th Mar 20202:18 pmRNSHolding(s) in Company
5th Mar 20204:01 pmRNSDoc re. Ordinary & Special Resolutions
4th Mar 20202:55 pmRNSResult of AGM
4th Mar 20207:00 amRNSAGM Trading Update
2nd Mar 202011:13 amRNSTotal Voting Rights
28th Feb 20201:32 pmRNSHolding(s) in Company
3rd Feb 202010:09 amRNSTotal Voting Rights
29th Jan 202012:16 pmRNSAdditional Listing
23rd Jan 20205:18 pmRNSDirector/PDMR Shareholding
21st Jan 202010:08 amRNSNotice of AGM
20th Jan 20204:40 pmRNSDirector/PDMR Shareholding
2nd Jan 20205:32 pmRNSTotal Voting Rights
23rd Dec 201910:50 amRNSHolding(s) in Company
18th Dec 201910:36 amRNSBlock listing Interim Review
17th Dec 20194:12 pmRNSHolding(s) in Company
17th Dec 20191:13 pmRNSDirector/PDMR Shareholding
17th Dec 20191:11 pmRNSDirector/PDMR Shareholding
17th Dec 20191:10 pmRNSDirector/PDMR Shareholding
17th Dec 20191:07 pmRNSDirector/PDMR Shareholding
17th Dec 20191:05 pmRNSDirector/PDMR Shareholding
17th Dec 20191:02 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.